Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: A systematic review and meta-analysis

American Journal of Transplantation

Volumn 14, Issue 10, 2014, Pages 2317-2327

  Murakami, N ^a   Riella, L V ^b   Funakoshi, T ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Calcineurin inhibitor (CNI); clinical research; complication: medical; immune modulation; immunosuppressant; immunosuppression; immunosuppressive regimens; kidney transplantation; mechanistic target of rapamycin (mTOR); metabolic; minimization; nephrology; practice; withdrawal

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ACUTE GRAFT REJECTION; ANEMIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY TRANSPLANTATION; MEDLINE; META ANALYSIS (TOPIC); METABOLIC COMPLICATION; METABOLIC DISORDER; NEW ONSET DIABETES AFTER TRANSPLANT; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TREND STUDY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; META ANALYSIS; OPPORTUNISTIC INFECTIONS;

HUMANS; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; RISK ASSESSMENT; TOR SERINE-THREONINE KINASES;

EID: 84908207626     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12852     Document Type: Review

References (55)

1. Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175-183.
2. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115-1123.
3. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
4. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837-847.
5. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA., Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006; 82: 1153-1162.
6. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ., Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
7. Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007; 83: 1027-1034.
8. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415-2421.
9. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H., Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378: 1419-1427.
10. Riella LV, Gabardi S, Chandraker A., Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant 2012; 12: 1975-1982.
11. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2013.
12. Pfizer Inc. Full prescribing information: Rapamune (sirolimus) oral solution and tablets. 2012. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=139. Accessed December 10, 2012.
13. Novartis Pharma. Full prescribing information: ZORTRESS (everolimus) tablets for oral use. 2013. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/zortress.pdf. Accessed February 25, 2013.
14. Moher D, Liberati A, Tetzlaff J, Altman DG;, PRISMA Group., Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
15. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522.
16. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531.
17. Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010; 89: 1511-1517.
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl 1): S62-S69.
19. Holdaas H, Fellstrom B, Jardine AG, Group AS., Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: Lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trial. Am J Transplant 2005; 5: 1574-1575.
20. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG., Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
22. Begg CB, Mazumdar M., Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
23. Egger M, Davey Smith G, Schneider M, Minder C., Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
24. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897-907.
25. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5: 2496-2503.
26. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755-3762.
27. Holdaas H, Rostaing L, Seron D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation 2011; 92: 410-418.
28. Mjornstedt L, Sorensen SS, von Zur Muhlen B, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation. Am J Transplant 2012; 12: 2744-2753.
29. Liu M, Zhang W, Gu M, et al. Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy. Transplant Proc 2007; 39: 1410-1415.
30. Silva HT Jr, Felipe CR, Garcia VD, et al. Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant 2013; 13: 3155-3163.
31. Bemelman FJ, de Maar EF, Press RR, et al. Minimization of maintenance immunosuppression early after renal transplantation: An interim analysis. Transplantation 2009; 88: 421-428.
32. Han F, Wu J, Huang H, et al. Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: A 4-year prospective study. Exp Clin Transplant 2011; 9: 42-49.
33. Pankewycz O, Leca N, Kohli R, et al. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: A prospective, protocol biopsy-guided study. Transplant Proc 2011; 43: 519-523.
34. Chhabra D, Alvarado A, Dalal P, et al. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. Am J Transplant 2013; 13: 2902-2911.
35. Kaposztas Z, Gyurus E, Kahan BD., New-onset diabetes after renal transplantation: Diagnosis, incidence, risk factors, impact on outcomes, and novel implications. Transplant Proc 2011; 43: 1375-1394.
36. Sterne JA, Gavaghan D, Egger M., Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119-1129.
37. Johnston O, Rose CL, Webster AC, Gill JS., Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418.
38. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876-1885.
39. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R., Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22: 2107-2118.
40. Syed NA, Khandelwal RL., Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem 2000; 211: 123-136.
41. Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS., The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006; 49: 2341-2349.
42. Kwon G, Marshall CA, Liu H, Pappan KL, Remedi MS, McDaniel ML., Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: Effects on cell cycle progression in rodent islets. J Biol Chem 2006; 281: 3261-3267.
43. Barlow AD, Nicholson ML, Herbert TP., Evidence for rapamycin toxicity in pancreatic beta-cells and a review of the underlying molecular mechanisms. Diabetes 2013; 62: 2674-2682.
44. Teutonico A, Schena PF, Di Paolo S., Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128-3135.
45. Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384-1392.
46. Laplante M, Sabatini DM., mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
47. Lamming DW, Sabatini DM., A central role for mTOR in lipid homeostasis. Cell Metab 2013; 18: 465-469.
48. Cole EH, Johnston O, Rose CL, Gill JS., Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008; 3: 814-821.
49. Hornum M, Lindahl JP, von Zur-Muhlen B, Jenssen T, Feldt-Rasmussen B., Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: A position statement from the nordic transplantation societies. Transpl Int 2013; 26: 1049-1060.
50. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031.
51. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 2005; 5: 2929-2936.
52. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.
53. KDIGO Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013; 3: 259-305.
54. Opelz G, Dohler B;, Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725-2731.
55. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-339.